A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions

HealthyObesity

Interventions

DRUG

BI 1820237

DRUG

semaglutide

DRUG

Placebo

DRUG

BI 456906

Trial Locations (1)

CRS Clinical Research Services Mannheim GmbH, Mannheim